Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

Front Pharmacol. 2021 Jul 16:12:732903. doi: 10.3389/fphar.2021.732903. eCollection 2021.

Authors

Daniel A Ladin¹, Eman Soliman^{1

2}, LaToya Griffin¹, Rukiyah Van Dross^{1

3}

Affiliations

¹ Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC, United States.
² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
³ Center for Health Disparities, East Carolina University, Greenville, NC, United States.

Abstract

[This corrects the article DOI: 10.3389/fphar.2016.00361.].

Keywords: cancer; cancer models; cannabinoids; clinical studies; clinical trials; endocannabinoids; in vivo; therapeutics.

Copyright © 2021 Ladin, Soliman, Griffin and Van Dross.

Publication types

Published Erratum